Dr Vinay Prasad will be FDA's top vaccine regulator. Controversial oncoologist-haematologist Vinay Prasad will be the FDA's top vaccine regulator. Apart from his extensive research and ...

Vinay Prasad, a critic of the Food and Drug Administration, has been tapped as the agency’s top regulator of vaccines, gene therapies and the blood supply. Prasad, a University of California at ...

The Food and Drug Administration (FDA) has tapped Vinay Prasad, a prominent critic of federal COVID-19 policies and a proponent of more stringent approval standards, to lead the agency’s ...

The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.

The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines and ...

FDA Commissioner Marty Makary on Tuesday named Indian-origin hematologist oncologist Vinay Prasad as the next director of the Center for Biologics and Research FDA Commissioner Marty Makary on ...

Prasad has criticized COVID vaccine mandates, agency leadership Biotech stocks fall, led by declines in Moderna shares Prasad to oversee regulation of biologic drugs, vaccines May 6 (Reuters ...

Find him on Twitter @GabeWhisnant. Dr. Vinay Prasad, a known critic of both the pharmaceutical industry and the Food and Drug Administration, has been appointed to lead the FDA's program ...

FDA Commissioner Marty Makary, M.D., has named Vinay Prasad, M.D., to the post, he said in a post on X. "Dr. Prasad brings the kind of scientific rigor, independence, and transparency we need at ...

WASHINGTON (AP) — Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to oversee the agency’s program for vaccines and ...

Vinay Prasad's appointment as CBER director has caused biotech stocks to fall due to concerns over potential regulatory changes. Prasad's history of criticizing FDA decisions suggests possible ...